397 related articles for article (PubMed ID: 19185005)
1. High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis.
Schaap FG; van der Gaag NA; Gouma DJ; Jansen PL
Hepatology; 2009 Apr; 49(4):1228-35. PubMed ID: 19185005
[TBL] [Abstract][Full Text] [Related]
2. A GAPDH-mediated trans-nitrosylation pathway is required for feedback inhibition of bile salt synthesis in rat liver.
Rodríguez-Ortigosa CM; Celay J; Olivas I; Juanarena N; Arcelus S; Uriarte I; Marín JJ; Avila MA; Medina JF; Prieto J
Gastroenterology; 2014 Nov; 147(5):1084-93. PubMed ID: 25066374
[TBL] [Abstract][Full Text] [Related]
3. A nontumorigenic variant of FGF19 treats cholestatic liver diseases.
Luo J; Ko B; Elliott M; Zhou M; Lindhout DA; Phung V; To C; Learned RM; Tian H; DePaoli AM; Ling L
Sci Transl Med; 2014 Jul; 6(247):247ra100. PubMed ID: 25080475
[TBL] [Abstract][Full Text] [Related]
4. Expression of hepatic Fibroblast Growth Factor 19 is enhanced in Primary Biliary Cirrhosis and correlates with severity of the disease.
Wunsch E; Milkiewicz M; Wasik U; Trottier J; Kempińska-Podhorodecka A; Elias E; Barbier O; Milkiewicz P
Sci Rep; 2015 Aug; 5():13462. PubMed ID: 26293907
[TBL] [Abstract][Full Text] [Related]
5. Circulating FGF19 closely correlates with bile acid synthesis and cholestasis in patients with primary biliary cirrhosis.
Li Z; Lin B; Lin G; Wu Y; Jie Y; Li X; Ko B; Chong Y; Luo J
PLoS One; 2017; 12(6):e0178580. PubMed ID: 28570655
[TBL] [Abstract][Full Text] [Related]
6. Antibody-mediated inhibition of fibroblast growth factor 19 results in increased bile acids synthesis and ileal malabsorption of bile acids in cynomolgus monkeys.
Pai R; French D; Ma N; Hotzel K; Plise E; Salphati L; Setchell KD; Ware J; Lauriault V; Schutt L; Hartley D; Dambach D
Toxicol Sci; 2012 Apr; 126(2):446-56. PubMed ID: 22268002
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast Growth Factor 21 Response in a Preclinical Alcohol Model of Acute-on-Chronic Liver Injury.
Christidis G; Karatayli E; Hall RA; Weber SN; Reichert MC; Hohl M; Qiao S; Boehm U; Lütjohann D; Lammert F; Karatayli SC
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360670
[TBL] [Abstract][Full Text] [Related]
8. Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression.
Song KH; Li T; Owsley E; Strom S; Chiang JY
Hepatology; 2009 Jan; 49(1):297-305. PubMed ID: 19085950
[TBL] [Abstract][Full Text] [Related]
9. An FXR Agonist Reduces Bile Acid Synthesis Independently of Increases in FGF19 in Healthy Volunteers.
Al-Khaifi A; Rudling M; Angelin B
Gastroenterology; 2018 Oct; 155(4):1012-1016. PubMed ID: 29928896
[TBL] [Abstract][Full Text] [Related]
10. Restoration of enterohepatic bile acid pathways in pregnant mice following short term activation of Fxr by GW4064.
Moscovitz JE; Kong B; Buckley K; Buckley B; Guo GL; Aleksunes LM
Toxicol Appl Pharmacol; 2016 Nov; 310():60-67. PubMed ID: 27609522
[TBL] [Abstract][Full Text] [Related]
11. The influences of cholecystectomy on the circadian rhythms of bile acids as well as the enterohepatic transporters and enzymes systems in mice.
Zhang F; Duan Y; Xi L; Wei M; Shi A; Zhou Y; Wei Y; Wu X
Chronobiol Int; 2018 May; 35(5):673-690. PubMed ID: 29381405
[TBL] [Abstract][Full Text] [Related]
12. Impaired Hepatic Adaptation to Chronic Cholestasis induced by Primary Sclerosing Cholangitis.
Milkiewicz M; Klak M; Kempinska-Podhorodecka A; Wiechowska-Kozlowska A; Urasinska E; Blatkiewicz M; Wunsch E; Elias E; Milkiewicz P
Sci Rep; 2016 Dec; 6():39573. PubMed ID: 28008998
[TBL] [Abstract][Full Text] [Related]
13. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man.
Lundåsen T; Gälman C; Angelin B; Rudling M
J Intern Med; 2006 Dec; 260(6):530-6. PubMed ID: 17116003
[TBL] [Abstract][Full Text] [Related]
14. The expression levels of plasma membrane transporters in the cholestatic liver of patients undergoing biliary drainage and their association with the impairment of biliary secretory function.
Shoda J; Kano M; Oda K; Kamiya J; Nimura Y; Suzuki H; Sugiyama Y; Miyazaki H; Todoroki T; Stengelin S; Kramer W; Matsuzaki Y; Tanaka N
Am J Gastroenterol; 2001 Dec; 96(12):3368-78. PubMed ID: 11774951
[TBL] [Abstract][Full Text] [Related]
15. Chenodeoxycholic Acid Modulates Bile Acid Synthesis Independent of Fibroblast Growth Factor 19 in Primary Human Hepatocytes.
Johansson H; Søndergaard JN; Jorns C; Kutter C; Ellis ECS
Front Endocrinol (Lausanne); 2020; 11():554922. PubMed ID: 33692750
[TBL] [Abstract][Full Text] [Related]
16. Effects of essential fatty acid deficiency on enterohepatic circulation of bile salts in mice.
Lukovac S; Los EL; Stellaard F; Rings EH; Verkade HJ
Am J Physiol Gastrointest Liver Physiol; 2009 Sep; 297(3):G520-31. PubMed ID: 19608735
[TBL] [Abstract][Full Text] [Related]
17. Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis.
Modica S; Petruzzelli M; Bellafante E; Murzilli S; Salvatore L; Celli N; Di Tullio G; Palasciano G; Moustafa T; Halilbasic E; Trauner M; Moschetta A
Gastroenterology; 2012 Feb; 142(2):355-65.e1-4. PubMed ID: 22057115
[TBL] [Abstract][Full Text] [Related]
18. The human gallbladder secretes fibroblast growth factor 19 into bile: towards defining the role of fibroblast growth factor 19 in the enterobiliary tract.
Zweers SJ; Booij KA; Komuta M; Roskams T; Gouma DJ; Jansen PL; Schaap FG
Hepatology; 2012 Feb; 55(2):575-83. PubMed ID: 21953282
[TBL] [Abstract][Full Text] [Related]
19. Disrupted Murine Gut-to-Human Liver Signaling Alters Bile Acid Homeostasis in Humanized Mouse Liver Models.
Chow EC; Quach HP; Zhang Y; Wang JZ; Evans DC; Li AP; Silva J; Tirona RG; Lai Y; Pang KS
J Pharmacol Exp Ther; 2017 Jan; 360(1):174-191. PubMed ID: 27789682
[TBL] [Abstract][Full Text] [Related]
20. Elevated hepatic multidrug resistance-associated protein 3/ATP-binding cassette subfamily C 3 expression in human obstructive cholestasis is mediated through tumor necrosis factor alpha and c-Jun NH2-terminal kinase/stress-activated protein kinase-signaling pathway.
Chai J; He Y; Cai SY; Jiang Z; Wang H; Li Q; Chen L; Peng Z; He X; Wu X; Xiao T; Wang R; Boyer JL; Chen W
Hepatology; 2012 May; 55(5):1485-94. PubMed ID: 22105759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
